Next 10 |
2024-04-26 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-17 10:24:12 ET Summary TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of TG Therapeutics' anti-CD20 MS treatment Briumvi were solid, generating $92 mill...
2024-04-16 16:59:57 ET More on Precision BioSciences Precision BioSciences stock falls after pricing $40M securities offering Precision BioSciences announces proposed public offering of common stock and warrants Seeking Alpha’s Quant Rating on Precision BioSci...
- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners ...
2024-04-01 10:00:18 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
2024-03-27 11:53:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Precision BioSciences (NASDAQ: DTIL ) just reported results for the fourth quarter of 2023. Precision BioSciences reported earnings per share of -$3.35. This was below the...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
2024-03-27 06:51:54 ET More on Precision BioSciences Precision BioSciences stock falls after pricing $40M securities offering Precision BioSciences announces proposed public offering of common stock and warrants Seeking Alpha’s Quant Rating on Precision BioSci...
- Initiated final IND/CTA enabling studies for lead in vivo gene editing program PBGENE-HBV; expect to submit IND and/or CTA in 2024 - Completed licensing agreements to monetize divested CAR T assets with Imugene, TG Therapeutics and Caribou Biosciences including nearly $50 million in upf...
2024-03-26 12:16:48 ET More on Precision BioSciences Precision BioSciences stock falls after pricing $40M securities offering Precision BioSciences announces proposed public offering of common stock and warrants Seeking Alpha’s Quant Rating on Precision BioSci...
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NYSE Market:
Precision BioSciences Inc. Website:
2024-04-26 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insertion - Precision exercised option to regain control of programs and intends to bring collaboration programs back to develop independently or with new partners ...